Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
Publication
, Journal Article
Vaios, EJ; Winter, SF; Muzikansky, A; Nahed, BV; Dietrich, J
Published in: Neuro-Oncology Advances
January 1, 2020
Duke Scholars
Published In
Neuro-Oncology Advances
DOI
EISSN
2632-2498
Publication Date
January 1, 2020
Volume
2
Issue
1
Publisher
Oxford University Press (OUP)
Citation
APA
Chicago
ICMJE
MLA
NLM
Vaios, E. J., Winter, S. F., Muzikansky, A., Nahed, B. V., & Dietrich, J. (2020). Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neuro-Oncology Advances, 2(1). https://doi.org/10.1093/noajnl/vdaa031
Vaios, Eugene J., Sebastian F. Winter, Alona Muzikansky, Brian V. Nahed, and Jorg Dietrich. “Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma.” Neuro-Oncology Advances 2, no. 1 (January 1, 2020). https://doi.org/10.1093/noajnl/vdaa031.
Vaios EJ, Winter SF, Muzikansky A, Nahed BV, Dietrich J. Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neuro-Oncology Advances. 2020 Jan 1;2(1).
Vaios, Eugene J., et al. “Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma.” Neuro-Oncology Advances, vol. 2, no. 1, Oxford University Press (OUP), Jan. 2020. Crossref, doi:10.1093/noajnl/vdaa031.
Vaios EJ, Winter SF, Muzikansky A, Nahed BV, Dietrich J. Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neuro-Oncology Advances. Oxford University Press (OUP); 2020 Jan 1;2(1).
Published In
Neuro-Oncology Advances
DOI
EISSN
2632-2498
Publication Date
January 1, 2020
Volume
2
Issue
1
Publisher
Oxford University Press (OUP)